DoxorubicinAntineoplastic AgentsAntibiotics, AntineoplasticRadiation DosageRadiation, IonizingRadiation InjuriesCell Line, TumorDose-Response Relationship, RadiationDrug Screening Assays, AntitumorRadiation ToleranceRadiationDrug Resistance, NeoplasmNeoplasmsRadiation ProtectionRadiation MonitoringApoptosisDrug CarriersCisplatinAntineoplastic Combined Chemotherapy ProtocolsCell SurvivalVincristineRazoxaneAntineoplastic Agents, PhytogenicDrug Delivery SystemsP-GlycoproteinTumor Cells, CulturedDrug Resistance, MultipleEtoposidePaclitaxelCyclophosphamideBreast NeoplasmsRadiation OncologyDose-Response Relationship, DrugMice, NudeXenograft Model Antitumor AssaysCombined Modality TherapyDNA DamageDrug Synergismgp100 Melanoma AntigenGamma RaysDaunorubicinCosmic RadiationRadiation Injuries, ExperimentalCell ProliferationEllipticinesVinblastineInhibitory Concentration 50Radiation PneumonitisRadiotherapyRadiation-Sensitizing AgentsDNA Topoisomerases, Type IIPolyethylene GlycolsFluorouracilNeoplasms, Radiation-InducedLeukemia P388ProdrugsCamptothecinBackground RadiationTreatment OutcomeBleomycinMitoxantroneCell CycleDrug ResistanceTime FactorsRadiotherapy DosageUltraviolet RaysMolecular StructureNanocapsulesNanoparticlesNeoplasm TransplantationRadiometryTumor Suppressor Protein p53Drug Administration ScheduleGene Expression Regulation, NeoplasticAnthracyclinesDrug DesignRadiation EffectsRadiation-Protective AgentsPrednisoneNanomedicineMultidrug Resistance-Associated ProteinsTopoisomerase II InhibitorsColonic NeoplasmsEnzyme InhibitorsMethotrexateMitomycinGenes, MDRDrug Evaluation, PreclinicalLung NeoplasmsTopoisomerase I InhibitorsCaspasesCaspase 3DNA RepairProto-Oncogene Proteins c-bcl-2TaxoidsTransplantation, HeterologousAntineoplastic Agents, AlkylatingNeoplasms, ExperimentalAdenocarcinomaPlatinum